The FDA has asked Eli Lilly for more data on liver injury associated with its newly approved obesity pill Foundayo.
FDA requires Eli Lilly to conduct post-marketing studies to assess safety, including potential heart and liver risks.
The request was reported on April 14, 2026, ahead of Foundayo's key obesity market launch.
Foundayo is an oral GLP-1 weight-loss pill recently made available through programs like LifeMD as of April 10, 2026.